124 related articles for article (PubMed ID: 11297239)
1. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors.
Doolittle ND; Muldoon LL; Brummett RE; Tyson RM; Lacy C; Bubalo JS; Kraemer DF; Heinrich MC; Henry JA; Neuwelt EA
Clin Cancer Res; 2001 Mar; 7(3):493-500. PubMed ID: 11297239
[TBL] [Abstract][Full Text] [Related]
2. First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate.
Neuwelt EA; Brummett RE; Doolittle ND; Muldoon LL; Kroll RA; Pagel MA; Dojan R; Church V; Remsen LG; Bubalo JS
J Pharmacol Exp Ther; 1998 Jul; 286(1):77-84. PubMed ID: 9655844
[TBL] [Abstract][Full Text] [Related]
3. Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption.
Neuwelt EA; Gilmer-Knight K; Lacy C; Nicholson HS; Kraemer DF; Doolittle ND; Hornig GW; Muldoon LL
Pediatr Blood Cancer; 2006 Aug; 47(2):174-82. PubMed ID: 16086410
[TBL] [Abstract][Full Text] [Related]
4. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity.
Muldoon LL; Pagel MA; Kroll RA; Brummett RE; Doolittle ND; Zuhowski EG; Egorin MJ; Neuwelt EA
Clin Cancer Res; 2000 Jan; 6(1):309-15. PubMed ID: 10656463
[TBL] [Abstract][Full Text] [Related]
5. In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity.
Neuwelt EA; Brummett RE; Remsen LG; Kroll RA; Pagel MA; McCormick CI; Guitjens S; Muldoon LL
Cancer Res; 1996 Feb; 56(4):706-9. PubMed ID: 8630999
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
7. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels.
Dickey DT; Wu YJ; Muldoon LL; Neuwelt EA
J Pharmacol Exp Ther; 2005 Sep; 314(3):1052-8. PubMed ID: 15951398
[TBL] [Abstract][Full Text] [Related]
8. Ototoxic protection of sodium thiosulfate: daily vs constant infusion.
Stocks RM; Gould HJ; Bush AJ; Dudney BW; Pousson M; Thompson JW
Otolaryngol Head Neck Surg; 2004 Jul; 131(1):115-9. PubMed ID: 15243567
[TBL] [Abstract][Full Text] [Related]
9. [Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention].
Montaguti M; Brandolini C; Ferri GG; Hatzopoulos S; Prete A; Pession A
Acta Otorhinolaryngol Ital; 2002 Feb; 22(1):14-8. PubMed ID: 12236007
[TBL] [Abstract][Full Text] [Related]
10. Preventing platinum-induced ototoxicity in children-is there a potential role for sodium thiosulfate?
Skinner R
Pediatr Blood Cancer; 2006 Aug; 47(2):120-2. PubMed ID: 16206212
[No Abstract] [Full Text] [Related]
11. [Effect of sodium thiosulfate on cisplatin-induced ototoxicity].
Lou WH
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1990 Aug; 25(4):208-10, 255. PubMed ID: 2076324
[TBL] [Abstract][Full Text] [Related]
12. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
Fortin D; Desjardins A; Benko A; Niyonsega T; Boudrias M
Cancer; 2005 Jun; 103(12):2606-15. PubMed ID: 15880378
[TBL] [Abstract][Full Text] [Related]
13. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
Häberle B; Bode U; von Schweinitz D
Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
[TBL] [Abstract][Full Text] [Related]
14. The incidence of hearing impairment after successful treatment of neuroblastoma.
Simon T; Hero B; Dupuis W; Selle B; Berthold F
Klin Padiatr; 2002; 214(4):149-52. PubMed ID: 12165893
[TBL] [Abstract][Full Text] [Related]
15. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
16. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma.
Parsons SK; Neault MW; Lehmann LE; Brennan LL; Eickhoff CE; Kretschmar CS; Diller LR
Bone Marrow Transplant; 1998 Oct; 22(7):669-74. PubMed ID: 9818694
[TBL] [Abstract][Full Text] [Related]
17. Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
Jahnke K; Kraemer DF; Knight KR; Fortin D; Bell S; Doolittle ND; Muldoon LL; Neuwelt EA
Cancer; 2008 Feb; 112(3):581-8. PubMed ID: 18072268
[TBL] [Abstract][Full Text] [Related]
18. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
19. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma.
Jehanne M; Lumbroso-Le Rouic L; Savignoni A; Aerts I; Mercier G; Bours D; Desjardins L; Doz F
Pediatr Blood Cancer; 2009 May; 52(5):637-43. PubMed ID: 19148943
[TBL] [Abstract][Full Text] [Related]
20. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.
Kushner BH; Cheung NK; Kramer K; Dunkel IJ; Calleja E; Boulad F
Bone Marrow Transplant; 2001 Sep; 28(6):551-6. PubMed ID: 11607767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
